XML 121 R100.htm IDEA: XBRL DOCUMENT v3.22.0.1
Taxes on Income - Reconciliation Between Effective Tax Rate and US Statutory Rate (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Amount      
U.S. statutory rate applied to income from continuing operations before taxes $ 2,915 $ 1,231 $ 1,506
Differential arising from:      
Foreign earnings (1,446) (965) (461)
GILTI and the foreign-derived intangible income deduction (75) 349 323
Tax settlements (275) (13) (139)
R&D tax credit (81) (108) (116)
Acquisition of VelosBio (9) 559 0
Acquisition of Pandion 356 0 0
Valuation allowances 102 37 115
Restructuring 61 105 39
Acquisition-related costs, including amortization 8 38 70
State taxes 2 57 (12)
Acquisition of OncoImmune 0 97 0
Acquisition of Peloton 0 0 209
Tax Cuts and Jobs Act of 2017 0 0 117
Other (37) (47) (86)
Taxes on income $ 1,521 $ 1,340 $ 1,565
Tax Rate      
U.S. statutory rate applied to income from continuing operations before taxes 21.00% 21.00% 21.00%
Differential arising from:      
Foreign earnings (10.40%) (16.50%) (6.40%)
GILTI and the foreign-derived intangible income deduction (0.50%) 6.00% 4.50%
Tax settlements (2.00%) (0.20%) (1.90%)
R&D tax credit (0.60%) (1.80%) (1.60%)
Acquisition of VelosBio (0.10%) 9.50% 0.00%
Acquisition of Pandion 2.60% 0.00% 0.00%
Valuation allowances 0.70% 0.60% 1.60%
Restructuring 0.40% 1.80% 0.50%
Acquisition-related costs, including amortization 0.10% 0.60% 1.00%
State taxes 0.00% 1.00% (0.20%)
Acquisition of OncoImmune 0.00% 1.70% 0.00%
Acquisition of Peloton 0.00% 0.00% 2.90%
Tax Cuts and Jobs Act of 2017 0 0 0.016
Other (0.20%) (0.80%) (1.20%)
Total, Tax Rate 11.00% 22.90% 21.80%